ASS1 and neoplasm: To determine whether ADI-PEG20 could slow tumor growth in vivo, ASS1-negative RKO cells were subcutaneously implanted into nude mice, which were then randomly allocated to either treatment (5IU of ADI-PEG20/animal/week) or vehicle control groups.